לונג
ONTX: Start of Phase 1 trials; very large gap to fill
This stock had 100M volume today-- which is unusual, therefore significant. I did some forensic analysis of their news and it appears that they had a phase 3 survival events failure which means that the meds they were testing did not increase the chances of survival among cancer patients.
Now they start over again (Phase 1) on their other cancer drugs.
I noticed that they tried to push these cancer drugs as potential COVID-19 treatments but nobody bought the news and it appears that the scientific community didn't really see any potential as a treatment.
I don't plan to take any positions in this stock but I am sure that this chart will be of interest to somebody.
Now they start over again (Phase 1) on their other cancer drugs.
I noticed that they tried to push these cancer drugs as potential COVID-19 treatments but nobody bought the news and it appears that the scientific community didn't really see any potential as a treatment.
I don't plan to take any positions in this stock but I am sure that this chart will be of interest to somebody.
הערה
ONTX is currently rated a "BUY" according to my scripts.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.